Maupas P, Werner B, Larouzé B, Millman I, London W T, O'Connell A, Blumberg B S
Lancet. 1975 Jul 5;2(7923):9-11. doi: 10.1016/s0140-6736(75)92951-7.
Antibody to hepatitis-B core antigen (anti-HBc) was assayed in the serum of patients with primary hepatic carcinoma (P.H.C.) and controls from Hong Kong, West Africa, and the United States. In each region the prevalence of anti-HBc was higher in P.H.C. patients than in controls, ranging from 70 to 95% in the patients and from 20 to 68% in the controls from Asia and Africa; 24% of P.H.C. patients and 4% of controls from the U.S. had anti-HBc. These data support the hypothesis that chronic infection with hepatitis-B virus is aetiologically related to P.H.C., especially in Asia and Africa, although other factors must also be involved.
对原发性肝癌（P.H.C.）患者以及来自中国香港、西非和美国的对照人群的血清进行了乙肝核心抗原抗体（抗-HBc）检测。在每个地区，原发性肝癌患者中抗-HBc的流行率均高于对照人群，亚洲和非洲患者中的抗-HBc流行率为70%至95%，对照人群中的流行率为20%至68%；美国原发性肝癌患者中有24%抗-HBc呈阳性，对照人群中有4%呈阳性。这些数据支持了乙肝病毒慢性感染在病因学上与原发性肝癌相关的假说，尤其是在亚洲和非洲，不过一定也涉及其他因素。
